FMC FMC (FMC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0000037785
Activist 13DCongress · 1Form 144 · 1
Insider buyers, 180 days
0
Funds added, last quarter
204
13F, latest reported quarter
What the filings say about FMC
Insiders, 180 days
-$16.0K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 2 sold
Latest: sale, 2026-07-10
Planned sales (Form 144), 90 days
$16.0K
1 notice
Activist stakes (13D), 180 days
1 filing
Largest: 20.0% of the class
FMC insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, FMC CORP insiders sold a net $16.0K of stock across 40 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Sep 13, 2023.
- The trade is 4.4% of the 28,513 shares held after it.
- No other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Corporate Controller Pfeiffer Nicholas sold about $16.0K of FMC on Sep 9, 2026; 204 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 92.0% of the 19,634 shares held after it.
- No other insider bought within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BARRY MICHAEL F bought about $249.9K of FMC on Mar 4, 2026, the largest insider purchase at the company since 2025; 204 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 50.8% of the 13,784 shares held after it.
- 1 other insider bought within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Raines John Mitchell bought about $96.4K of FMC on Nov 13, 2025; 1 other insider bought within 30 days and 204 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Mar 5, 2025.
- +7.4% median (+7.4% mean) 90-day return after 2 previous buys.
- The trade is 43.1% of the 23,227 shares held after it.
- 1 other insider bought within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DAVIDSON CAROL ANTHONY bought about $136.0K of FMC on Nov 5, 2025; 1 other insider bought within 30 days and 204 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 18, 2025.
- The trade is 11.5% of the 33,044 shares held after it.
- No other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP & Chief HRO Scanlan Jacqueline sold about $128.9K of FMC on Sep 29, 2025; 204 funds added in the latest 13F quarter.40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$16.0K over 180 days
-$16.0K over 90 days
more than 60% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
204 funds bought in last quarter
more than 90% of Pharma & Biotech
Revenue
-18.3% year over year
below 68% of Pharma & Biotech
Margin
-64.6% net margin
below 53% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
31.3% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 97% of Pharma & Biotech
The situation: each line is one rule over one dataset
Tessenderlo Group NV disclosed a 5%+ stake (20.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FMC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-84.5%12M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FMC: institutional holders (13F)
13F holdings, latest reported quarter
21,535,604 sh
$247.7M
8,021,709 sh
$91.1M
7,719,466 sh
$88.8M
6,508,595 sh
$75.4M
5,758,841 sh
$66.2M
Congress trades in FMC
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-07-10 · disclosed 7 days later
$1,001 - $15,000
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-09-25 · disclosed 27 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Tessenderlo Group NV
Activist 13D · 2026-09-25
20.0%
Luc Jules R Tack
Activist 13D · 2026-09-25
20.0%
FMC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Pfeiffer Nicholas
Filed 2026-09-09
$16.0K
FMC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P SmallCap Materials ETF
$470.9K position · as of 2026-05-31
2.2%
EP Emerging Markets Fund
$1.6M position · as of 2026-07-31
1.2%
Invesco Zacks Multi-Asset Income ETF
$979.3K position · as of 2026-07-31
0.8%
S&P SmallCap 600 Pure Value Fund
$56.4K position · as of 2026-06-30
0.5%
Fidelity Agricultural Productivity Fund
$231.2K position · as of 2026-05-31
0.5%
Federated Hermes MDT Small Cap Core Fund
$10.5M position · as of 2026-07-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mark Douglas
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$9.6M
-$5.6M
$2.4M
-41%
+24%
2022
$11.1M
$16.2M
$2.3M
+12%
+12%
2021
$8.5M
$7.0M
$1.9M
-3%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $16.0K sold by insiders over 180 days, 204 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $16.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
FMC financials
Revenue growth
-18.3%
XBRL, annual
Net margin
-64.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FMC
| FY Dec 2025 | $3.5B |
| FY Dec 2024 | $4.2B |
| FY Dec 2023 | $4.5B |
| FY Dec 2022 | $5.8B |
| FY Dec 2021 | $5.0B |
| Jun 2026 | $867.1M |
| Mar 2026 | $758.6M |
| Dec 2025 | $1.1B |
| Sep 2025 | $542.2M |
| Jun 2025 | $1.1B |
| Mar 2025 | $791.4M |
| Dec 2024 | $1.2B |
| Sep 2024 | $1.1B |
At each fiscal year end
Single quarter
Net margin, TTM
-84.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FMC
| FY Dec 2025 | -64.6% |
| FY Dec 2024 | +8.0% |
| FY Dec 2023 | +29.5% |
| FY Dec 2022 | +12.7% |
| FY Dec 2021 | +14.7% |
| Jun 2026 | -21.5% |
| Mar 2026 | -37.1% |
| Dec 2025 | -158.8% |
| Sep 2025 | -105.0% |
| Jun 2025 | +6.3% |
| Mar 2025 | -2.0% |
| Dec 2024 | -1.3% |
| Sep 2024 | +6.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM FMC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
2.62x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity FMC
| FY Dec 2025 | 1.97x |
| FY Dec 2024 | 0.75x |
| FY Dec 2023 | 0.90x |
| FY Dec 2022 | 0.97x |
| FY Dec 2021 | 1.02x |
| Jun 2026 | 2.62x |
| Mar 2026 | 2.49x |
| Dec 2025 | 1.97x |
| Sep 2025 | 1.20x |
| Jun 2025 | 0.95x |
| Mar 2025 | 0.91x |
| Dec 2024 | 0.75x |
| Sep 2024 | 0.88x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt FMC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-91.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FMC
| FY Dec 2025 | -68.3% |
| FY Dec 2024 | +7.7% |
| FY Dec 2023 | +33.9% |
| FY Dec 2022 | +22.7% |
| FY Dec 2021 | +24.3% |
| Jun 2026 | -91.4% |
| Mar 2026 | -80.7% |
| Dec 2025 | -68.3% |
| Sep 2025 | -12.8% |
| Jun 2025 | +2.2% |
| Mar 2025 | +7.6% |
| Dec 2024 | +7.7% |
| Sep 2024 | +36.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-25.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FMC
| FY Dec 2025 | -21.0% |
| FY Dec 2024 | +2.9% |
| FY Dec 2023 | +11.4% |
| FY Dec 2022 | +6.7% |
| FY Dec 2021 | +7.1% |
| Jun 2026 | -25.7% |
| Mar 2026 | -23.6% |
| Dec 2025 | -21.0% |
| Sep 2025 | -4.4% |
| Jun 2025 | +0.8% |
| Mar 2025 | +2.8% |
| Dec 2024 | +2.9% |
| Sep 2024 | +12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital FMC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +16.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-26.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FMC
| FY Dec 2025 | -22.4% |
| FY Dec 2024 | +5.9% |
| FY Dec 2023 | +7.0% |
| FY Dec 2022 | +15.8% |
| FY Dec 2021 | +14.3% |
| Jun 2026 | -26.0% |
| Mar 2026 | -25.1% |
| Dec 2025 | -22.4% |
| Sep 2025 | +0.3% |
| Jun 2025 | +6.4% |
| Mar 2025 | +5.8% |
| Dec 2024 | +5.9% |
| Sep 2024 | +3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FMC
| FY Dec 2025 | n/a |
| FY Dec 2024 | 17.87x |
| FY Dec 2023 | 5.99x |
| FY Dec 2022 | 21.44x |
| FY Dec 2021 | 19.14x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 52.19x |
| Mar 2025 | 16.10x |
| Dec 2024 | 17.87x |
| Sep 2024 | 5.67x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.4B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value FMC
| FY Dec 2025 | $5.2B |
| FY Dec 2024 | $9.1B |
| FY Dec 2023 | $11.5B |
| FY Dec 2022 | $18.3B |
| FY Dec 2021 | $16.5B |
| Jun 2026 | $5.2B |
| Mar 2026 | $6.3B |
| Dec 2025 | $5.2B |
| Sep 2025 | $8.2B |
| Jun 2025 | $8.9B |
| Mar 2025 | $9.0B |
| Dec 2024 | $9.1B |
| Sep 2024 | $11.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield FMC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FMC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.07x |
| FY Dec 2022 | 15.39x |
| FY Dec 2021 | 0.53x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.5B | $4.2B | $4.5B | $5.8B |
| Gross profit | $1.3B | $1.6B | $1.8B | $2.3B |
| Operating income | -$1.6B | $506.5M | $555.6M | $1.1B |
| Net income | -$2.2B | $341.1M | $1.3B | $736.5M |
| EPS (diluted) | -17.88 | 2.72 | 10.53 | 5.81 |
| Cash | $584.5M | $357.3M | $302.4M | $572.0M |
| Long-term debt | $2.8B | $3.0B | $3.0B | $2.7B |
| Buybacks | $0 | $0 | $75.0M | $100.0M |
| Dividends paid | $291.3M | $290.6M | $290.5M | $267.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
FMC Stock Sonar score 6/7 axes
Find similar shapesCompareFMC ranks highest on profitability (56th percentile) and institutional and government (50th), and lowest on risk and compliance (3rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FMC filings, in plain words
Are FMC insiders buying or selling FMC?
In the 180 days to 2026-10-28, FMC insiders were net sellers, a net $16.0K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded FMC?
Yes. In the year to 2026-10-28, 1 House member disclosed buying FMC and 2 House members disclosed selling it; the latest on record is a sale by Dan Newhouse dated 2026-07-10.
Are there planned insider sales of FMC?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $16.0K of stock; the latest, by Pfeiffer Nicholas, was filed 2026-09-09.
Read the full summary
In the 180 days to 2026-10-28, FMC insiders were net sellers of FMC, a net $16.0K across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-28, 1 member of Congress disclosed buying FMC and 2 members disclosed selling it; the latest on record is a sale by Dan Newhouse dated 2026-07-10. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $16.0K of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 20.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
